Ritanserin

A selective and potent serotonin-2 antagonist that is effective in the treatment of a variety of syndromes related to anxiety and depression. The drug also improves the subjective quality of sleep and decreases portal pressure.

Also Known As:

6-(2-(4-(Bis(4-fluorophenyl)methylene)-1-piperidinyl)ethyl)-7-methyl-5H-thiazolo(3,2-a)pyrimidin-5-one; R-55667; Ritanserin Hydrochloride; Ritanserin Tartrate; R 55667; R55667; 5H-Thiazolo(3,2-a)pyrimidin-5-one, 6-(2-(4-(bis(4-fluorophenyl)methylene)-1-piperidinyl)ethyl)-7-methyl-

Networked: 209 relevant articles (20 outcomes, 46 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Pyrimidines: 510
    - Pyrimidinones: 71
      - Ritanserin: 209
        RLM001
  - Piperidines: 17
    - Ritanserin: 209
      - RLM001

Experts

1.	Harris, Thurl E: 3 articles (01/2022 - 01/2017)
2.	Purow, Benjamin W: 2 articles (01/2022 - 01/2017)
3.	Poyurovsky, Michael: 2 articles (06/2020 - 06/2003)
4.	Weizman, Abraham: 2 articles (06/2020 - 06/2003)
5.	Boroda, Salome: 2 articles (01/2018 - 01/2017)
6.	Ohno, Yukihiro: 2 articles (06/2017 - 04/2015)
7.	Shimizu, Saki: 2 articles (06/2017 - 04/2015)
8.	Guimarães, F S: 2 articles (05/2010 - 03/2005)
9.	Akhondzadeh, Shahin: 2 articles (12/2008 - 06/2003)
10.	Nurse, Colin A: 2 articles (02/2007 - 09/2003)

Related Diseases

1.	Schizophrenia (Dementia Praecox) 12/12/2008 - "The present study indicates ritanserin as a potential adjunctive treatment strategy for the negative symptoms of schizophrenia. " 12/12/2008 - "Effect of ritanserin, a 5HT2A/2C antagonist, on negative symptoms of schizophrenia: a double-blind randomized placebo-controlled study." 02/01/1994 - "The effect of the selective serotonin-2 antagonist ritanserin was investigated in an open study of patients with schizophrenia. " 02/01/1994 - "An open clinical and biochemical study of ritanserin in acute patients with schizophrenia." 10/01/1993 - "The effectiveness of ritanserin, a selective 5-HT2 and 5-HT1c antagonist, in reducing negative symptoms in schizophrenia was investigated in a double-blind, placebo-controlled trial. "
2.	Dysthymic Disorder 01/01/1988 - "Ritanserin, a selective and potent serotonin-2 antagonist, is effective in the treatment of a variety of syndromes related to anxiety and depression, including dysthymic disorder. " 04/01/1991 - "Thirty patients suffering from dysthymic disorder participated in a 6-week double-blind trial comparing ritanserin 10 mg and placebo. " 04/01/1991 - "5-HT2 receptor antagonism in dysthymic disorder: a double-blind placebo-controlled study with ritanserin." 10/01/1993 - "Patients on ritanserin achieved a progressive improvement of their dysthymia. " 10/01/1986 - "Ritanserin is an investigational serotonin-S2 receptor antagonist with activity in a variety of psychiatric disturbances characterized by dysthymia or anxiety. "
3.	Parkinsonian Disorders (Parkinsonism) 01/01/1986 - "Open pilot trial of ritanserin in parkinsonism." 01/01/1989 - "The stimulatory effect of ritanserin on midbrain DA systems might contribute to some of its clinical effects, such as improvement of mood, drive and motivation as well as its therapeutic actions in parkinsonism and type II schizophrenia." 02/01/2010 - "The many interactions between the serotoninergic and dopaminergic systems require the implementation of clinical studies on the complex motor impact of serotoninergic treatments, which may aggravate the parkinsonian syndrome while improving gait (as is the case with paroxetine and ritanserin). " 12/01/1990 - "The Mindham Rating Scale was used to assess symptoms of parkinsonism; at week 3, ritanserin was superior to orphenadrine (p less than 0.03) and to placebo (p less than 0.01). " 12/01/1990 - "The results confirm previous observations of the therapeutic efficacy of ritanserin on neuroleptic-induced parkinsonism, and support the hypothesis that serotonin influences extrapyramidal physiopathology."
4.	Catalepsy 11/01/1996 - "It was found that ritanserin (2 mg kg-1 s.c.) enhanced the raclopride (0.1 mg kg-1 s.c.)-induced suppression of CAR without affecting raclopride-induced catalepsy at either maximal (4 mg kg-1 s.c.) or submaximal (0.2 mg kg-1 s.c.) doses. " 12/27/1995 - "The effects of DOI on raclopride-induced catalepsy were fully antagonized by pretreatment with the 5-HT2A/C receptor antagonist, ritanserin (2 mg kg-1 s.c.). " 04/27/1988 - "Stereotaxic injection of SCH 23390 (D-1 antagonist), but not water or ritanserin (5-HT antagonist), into all parts of the caudate-putamen, elicited an immediate and often long-lasting catalepsy in 79% of rats. " 04/30/2008 - "Furthermore, DOI and amperozide, but not ritanserin, reduced the haloperidol-induced catalepsy. " 05/01/1997 - "8-OH-DPAT (0.1 mg/kg, SC) given 2.5 h after, and ritanserin (0.63 and 1.25 mg/kg, IP), given 15 min prior to HAL, significantly reduced the neuroleptic-induced catalepsy. "
5.	Alcoholism (Alcohol Abuse) 01/01/1994 - "The results of a recent double-blind, placebo-controlled, trial indicated that ritanserin did not induce aversion to drink alcohol in normal volunteers who display social drinking, but are not suffering alcohol dependence. " 09/01/2003 - "Ritanserin, a 5-HT(2) antagonist, does not appear to be an efficacious treatment for alcoholism at pharmacologically relevant clinical doses. " 07/01/2000 - "Ritanserin in Alcoholism Work Group." 02/01/1999 - "In a placebo-controlled, randomized, double-blind international multicenter study 493 patients with moderate or severe alcohol dependence (DSM-III-R) were treated with three doses of ritanserin 2.5 mg/day (n = 122), 5 mg/day (n = 123), 10 mg/day (n = 126), or placebo (n = 122) over a period of 6 months. " 02/01/1999 - "Ritanserin in Alcoholism Work Group."

Related Drugs and Biologics

1.	Serotonin (5 Hydroxytryptamine)
2.	Serotonin 5-HT2 Receptor Antagonists
3.	Antipsychotic Agents (Antipsychotics)
4.	Ketanserin
5.	Serotonin Antagonists
6.	Haloperidol (Haldol)
7.	Dopamine (Intropin)
8.	5-HT2A Serotonin Receptor (5 HT2A Receptor)
9.	Fluoxetine (Prozac)
10.	Anti-Anxiety Agents (Anxiolytics)

Related Therapies and Procedures

1.	Therapeutics
2.	Ligation
3.	Drug Therapy (Chemotherapy)
4.	Secondary Prevention
5.	Intravenous Administration